Physician profile
Jeffrey A Dash
NPI 1922189224
$7,233.86
in general payments reported to CMS, 2019-2025
36 companies · $932 in 2025
The $932 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $706 · 2021: $1,175 · 2022: $1,324 · 2023: $1,286 · 2024: $1,258 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,475.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $802.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $799.36 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $667.43 | 2021-2025 | Ubrelvy, Synthroid |
| Astrazeneca Pharmaceuticals LP | $638.65 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $631.67 | 2022-2025 | |
| Pfizer INC. | $628.16 | 2019-2025 | |
| Amgen INC. | $566.89 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $392.37 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $291.94 | 2019-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $246.56 | 2022-2024 | Rexulti |
| Allergan, INC. | $208.58 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $195.52 | 2019-2025 | Capvaxive |
| Exact Sciences Corporation | $134.41 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.37 | 2020-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $89.36 | 2021-2023 | Nexletol |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $83.85 | 2022-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $78.13 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $75.65 | 2021 | |
| Idorsia Pharmaceuticals US INC | $70.21 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $64.65 | 2019-2022 | |
| Ibsa Pharma INC. | $51.01 | 2019-2023 | Tirosint, Licart |
| Currax Pharmaceuticals LLC | $40.29 | 2022-2023 | Contrave |
| Therapeuticsmd, INC. | $39.75 | 2019 | |
| Sanofi Pasteur INC. | $35.21 | 2019-2023 | |
| Inogen, INC. | $34.29 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| E.R. Squibb & Sons, L.L.C. | $34.00 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.66 | 2022 | |
| Almatica Pharma LLC | $32.09 | 2024 | Teriparatide |
| Jazz Pharmaceuticals INC. | $29.32 | 2021 | |
| Lundbeck LLC | $27.77 | 2022 | |
| Sumitomo Pharma America, INC. | $18.66 | 2025 | Gemtesa |
| Radius Health, INC. | $17.05 | 2024 | Tymlos |
| Pbg Puerto Rico LLC | $16.03 | 2021 | |
| Genentech USA, INC. | $15.98 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.22 | 2022 | |
| Aytu Biopharma, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Dash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.